A post-CNS5 study suggests “oligosarcoma, IDH-mutant” as highly distinct from conventional oligodendroglioma on multiple levels including histology, epigenetic-, proteomic- and molecular profiles. The gene discussed is IDH2; the disease is oligodendroglioma.